Aeglea BioTherapeutics · pitchdeck
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides
56 pages · 4 arc beats · 3 loops
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides
Aeglea BioTherapeutics · 2023-09 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
12468101214161820222426283032343638404244464850525456
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 56 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits — 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits — 0/1 slides
Agitate (Make it worse) 8 slides 100% 8/8 slides 100% 8/8 slides · 42 hits — 0/8 slides
37.5% 3/8 slides 87.5% 7/8 slides 100% 8/8 slides · 15 hits 75% 6/8 slides · 7 hits Solution (Provide relief) 35 slides 100% 35/35 slides 100% 35/35 slides · 174 hits — 0/35 slides
34.3% 12/35 slides 68.6% 24/35 slides 100% 35/35 slides · 41 hits 31.4% 11/35 slides · 12 hits Impact & Next Steps 12 slides 100% 12/12 slides 100% 12/12 slides · 54 hits — 0/12 slides
75% 9/12 slides 50% 6/12 slides 100% 12/12 slides — 0/12 slides
Slide inventory
56 every slide · same image gating as the playbook
01
The slide features both the Aeglea and Spyre Therapeutics logos, indicating a transition or merger context.front_matter
05
The slide uses a pipeline chart format to show the development status of seven different programs.plan_implementation
07
The slide uses a donut chart to illustrate market growth from 2021 to 2028.size_opportunity
08
The chart uses a visual metaphor of an arrow pointing from current standard of care (SOC) to a higher efficacy/convenience target.frame_problem
Open slide detailBeat · Problem (Identify pain)
09
The slide uses a numbered list format to present strategic pillars.present_framework
Open slide detailBeat · Agitate (Make it worse)
10
The slide uses a visual representation of an antibody molecule with callouts to specific engineering improvements, supported by a scatter plot showing clinical present_solution
11
Uses a visual metaphor of antibody combination to explain the therapeutic strategy.cite_precedent
12
The slide uses a Venn diagram to represent the intersection of genetic targets and a bar chart to demonstrate the efficacy of patient selection.cite_precedent
13
The slide uses a Gantt-style pipeline visualization to show progress of seven distinct programs.plan_implementation
14
The slide uses a Gantt-style layout to show progress across Discovery, IND-Enabling, and Clinical stages.plan_implementation
15
Includes a KOL quote and two charts: a bar chart for global sales and a line chart for market share.show_traction
16
The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).compare_peers
17
The slide uses a checkmark/arrow matrix to highlight competitive differentiation.compare_peers
18
The slide uses a standard antibody diagram to annotate specific engineering improvements.present_solution
19
Includes structural visualization of the epitope and two dose-response curves.present_solution
20
The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.analyze_data
Open slide detailBeat · Solution (Provide relief)
21
The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.show_traction
Open slide detailBeat · Solution (Provide relief)
22
The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).compare_peers
Open slide detailBeat · Solution (Provide relief)
23
Uses a visual timeline/comparison to contrast current standard of care with the proposed product.compare_peers
Open slide detailBeat · Solution (Provide relief)
24
The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.compare_peers
Open slide detailBeat · Solution (Provide relief)
25
Data from GEMINI 1 study; highlights that higher exposure does not necessarily correlate with higher remission rates.analyze_data
Open slide detailBeat · Solution (Provide relief)
26
The slide uses a 2x2 grid to summarize the program's value proposition.present_solution
Open slide detailBeat · Solution (Provide relief)
27
The slide uses peer benchmarking to justify valuation growth expectations based on clinical trial phases.compare_peers
Open slide detailBeat · Solution (Provide relief)
28
The table highlights the competitive positioning of SPY001, specifically emphasizing its subcutaneous administration profile.compare_peers
29
The chart compares preference share between Naïve and Switch patients for four different drug profiles.cite_precedent
Open slide detailBeat · Solution (Provide relief)
30
The slide uses a Gantt-style pipeline visualization to show progress from discovery to clinical stages for seven distinct programs.plan_implementation
Open slide detailBeat · Solution (Provide relief)
31
The chart uses a color-coded safety gradient on the Y-axis and efficacy percentages on the X-axis.compare_peers
Open slide detailBeat · Solution (Provide relief)
32
The slide uses a checkmark-based comparison matrix to highlight SPY002's superior profile.compare_peers
Open slide detailBeat · Solution (Provide relief)
33
The slide uses an antibody diagram to annotate specific technical improvements (half-life extension and formulation).present_solution
Open slide detailBeat · Solution (Provide relief)
34
The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant developmentcompare_peers
Open slide detailBeat · Solution (Provide relief)
35
The slide uses two distinct chart types: a dose-response curve (sigmoidal) and a scatter plot to demonstrate potency and specificity.present_solution
Open slide detailBeat · Solution (Provide relief)
36
The slide uses a 2x2 grid to summarize the program's value proposition.present_solution
Open slide detailBeat · Solution (Provide relief)
37
The slide uses a mountain-like diagram to represent sequential or cumulative expansion of indications.plan_implementation
Open slide detailBeat · Solution (Provide relief)
38
The slide uses a Gantt-style visualization to show the progression of various IBD programs.plan_implementation
Open slide detailBeat · Solution (Provide relief)
39
The slide uses a biological process diagram to illustrate the mechanism of action for three distinct drug candidates.present_solution
Open slide detailBeat · Solution (Provide relief)
40
The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.compare_peers
Open slide detailBeat · Solution (Provide relief)
41
The slide uses a comparison framework to highlight the competitive advantage of Spyre's gut-selective approach.compare_peers
Open slide detailBeat · Solution (Provide relief)
42
The slide uses a process flow diagram to illustrate the clinical trial strategy for SPY001 and SPY003.plan_implementation
Open slide detailBeat · Solution (Provide relief)
43
The slide uses a visual representation of a bispecific or combination antibody structure.present_solution
Open slide detailBeat · Solution (Provide relief)
44
The slide uses a Venn diagram to show target overlap and a hierarchical tree diagram to show diagnostic-driven treatment selection.present_solution
Open slide detailBeat · Solution (Provide relief)
45
The slide uses a comparative bar chart structure to validate the efficacy of genetic companion diagnostics (CDx) in improving clinical outcomes.show_traction
Open slide detailBeat · Impact & Next Steps
47
The slide includes a section for Management team and a section for Board of Directors, with headshots and titles for each individual, followed by a logo grid ofother
Open slide detailBeat · Impact & Next Steps
48
The slide uses a table-based timeline structure to map drug candidates (SPY001-004) against expected clinical milestones.plan_implementation
Open slide detailBeat · Impact & Next Steps
49
The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).compare_peers
Open slide detailBeat · Impact & Next Steps
50
The table maps historical M&A deal values to Spyre's internal pipeline milestones.compare_peers
Open slide detailBeat · Impact & Next Steps
52
The slide highlights the partnership with Paragon Therapeutics, detailing its founding, team size, operational capacity, program count, and the spin-out of Apogother
Open slide detailBeat · Impact & Next Steps
53
The slide uses a series of icons to represent different scientific methodologies.present_solution
Open slide detailBeat · Impact & Next Steps
54
The central graphic is an antibody structure inside a pentagon, representing the five optimization pillars.present_solution
Open slide detailBeat · Impact & Next Steps
55
The slide uses a split-screen diagram to contrast physiological affinity vs high affinity in the context of FcRn-mediated antibody recycling.present_solution
Open slide detailBeat · Impact & Next Steps
56
The slide uses a scatter plot to show correlation between Cyno and Human half-lives, and bar charts to compare ADA (Anti-Drug Antibody) rates.show_traction
Open slide detailBeat · Impact & Next Steps